Table 4.
Medication | Metabolism | Elimination half-life | Onset of action after consumption (minutes) | Commentsa |
---|---|---|---|---|
Dexmedetomidine | CYP2A6 and glucoronidation | 3 hours (prolonged in hepatic impairment) | 5–15 (5–10 and 15 with and without loading dose administration) | Potentially significant hypotension and bradycardia or hypertension that do not resolve quickly upon abrupt discontinuation which occur more commonly in patients with cardiovascular instability or hypovolemia; rapid administration of loading dose may be associated with cardiovascular instability, tachycardia, bradycardia, or heart-block; does not induce the deep sedation needed for neuromuscular blockade |
Clonidine | Hepatic metabolism to inactive metabolites | 12–16 hours (41 hours in renal impairment) | 10 | Causes bradycardia, hypotension, and xerostomia; use with caution in patients with cardiovascular and cerebrovascular diseases; CNS depressant |
Notes:
Drugs that alter the blood pressure level can affect hypertensive or hypotensive effect of alpha2 agonists. Tricyclic antidepressants can desensitize alpha2 adrenoreceptors and should be stopped 3 weeks prior to use of these two drugs.
Abbreviation: CNS, central nervous system.